



27th March 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
“Exchange Plaza”, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

SCRIP CODE: 543748

SYMBOL: AARTIPHARM

**Sub: Completion of US-FDA Inspection at
Unit-IV, Tarapur of Aarti Pharmalabs Limited**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (US FDA) inspected Unit-IV of Aarti Pharmalabs Limited, situated at Plot No. E-50, 50/1, 59/1, MIDC, Tarapur, Tal. & District Palghar, Maharashtra - 401506.

At the end of this inspection which concluded on 27th March 2026, a ‘Form 483’ was issued with 01 (One) observation. This observation is procedural in nature. The corrective and preventive actions for the observation along with compliance will be submitted to the US FDA within the stipulated period.

Please take the information on record.

Yours faithfully,
For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565